PuniCore

PuniCore is a South Korean biotechnology company specializing in the development of Urolithin A-based therapeutics for age-related and inflammatory diseases. The company was founded as a spin-off from the Korea Research Institute of Bioscience and Biotechnology (KRIBB) to commercialize research on mitochondrial health and mitophagy. PuniCore's proprietary platform enables the production of high-purity Urolithin A and the design of novel derivatives with improved bioavailability and efficacy. Their current pipeline includes preclinical programs for sarcopenia, Alzheimer's disease, and inflammatory bowel disease. By targeting mitochondrial dysfunction, PuniCore aims to provide innovative solutions for muscle wasting and neurodegeneration.